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opportunities to grow. On the other side, the fierce competition among biosimilars 
with the same reference biologics and upcoming MNC’s next generation antibody 
therapies are also putting a threat to biosimilar market as a whole. ConClusions: 
If pathways cannot be tailor-made for biosimilars in the future, thus hinders the fast 
launch of biosimilar products in China, population may not be able to enjoy more 
cost effective treatments and government may also lose the chance to benefit from 
the saving of the total health care expenditure.
PHP97
Current Situation of HealtH Care organizationS’ WaSte 
ManageMent
Gombojav E., Bayart N.E., Radnaa O., Choijiljav D., Nemekhee O.
Health Sciences University of Mongolia, Ulaanbaatar, Mongolia
objeCtives: There are challenges to assess the current situation of health care 
organizations’ waste management by the level and to formulate methods for fur-
ther improvement. Thus, purpose of this assessment study was to formulate ref-
erence about methods to improve current situation of health care organizations’ 
waste management. Methods: Study was done by the descriptive method among 
39 health care organizations using study forms, as questionnaires, checklist and 
tests. Results: In Ulaanbaatar waste disposal company is 100% responsible for 
hazardous waste of health care organizations, but 50% of domestic waste are taken 
care by hospitals themselves. However, in rural areas 48.7- 64% of hospitals and 
57.1% of health care centers are responsible for both their domestic and hazardous 
waste. 50% of hospitals drain the liquid waste into main sewage and liquid waste 
from laboratory are drained into central sewage after disinfection. Waste manage-
ment team works in 66.7% of hospitals, and nurses and dry-nurses are responsible 
in collecting of waste in 97.4% of hospitals. The team consists of 1-3 people in 
50% of hospitals, 4-6 people in 39.5% of hospitals but more people in tertiary level 
hospitals. ConClusions: Legal documents about waste management of health 
care organizations are approved; most secondary and tertiary level health care 
organizations have workers responsible for waste. They have developed plans to 
improve the “Waste management” and installed waste registration system. Despite 
setting up the temporary storages at hospitals and health care centers, they still 
need improvement. Although any equipment with mercury has been prohibited 
to use in health care organizations, 50% of hospitals are still using and it has been 
difficult to collect, transport and dispose mercury containing waste.
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objeCtives: This study is designed to review and to compare the concept and con-
tent of market access in both western and Chinese pharmaceutical environments, 
and further endeavor to clarify the responsibilities of each stakeholder in China to 
help providing better drug accessibility and affordability for the people. Methods: 
A literature review was undertaken to understand comprehensively the current 
market access protocols in mature markets as well as in China. Industry interviews, 
consulting surveys and data analysis were also conducted to collect first-hand data 
for comparison. Results: Unlike developed countries, where drug market access 
includes reimbursement and lots of patient access schemes, the market access of 
pharmaceuticals in China has a much broader scope, ranging from pricing, reim-
bursement, tendering, to hospital listing, etc, which indicates drug market access 
in China is a highly fragmented process and involves a lot of different govern-
ment departments. The centralized government management style, a historical 
consequence of the transformation from planned economy to market economy, 
is most attributable to this phenomenon. As a result, civil society, such as NGOs 
and academic institutions are relatively weaker compared to western countries, 
and they are not able to take intrinsically influential roles during market access 
decision-making process. This further leads to a high administration-oriented and 
low market-oriented drug market access present circumstance. Consequently, the 
timeline of drug market access in China is much longer than that of the mature 
market. ConClusions: The definition of market access in China needs to be re-
defined and global perspectives shall be incorporated. A re-structured concept will 
better serve China’s changing environment.
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objeCtives: Even the Ministry of Health is taking its attention to improve quality 
and safety of medical services, developing and implementing relevant policy and 
directions, quantity of complaints and occupational mistakes coming from citizens 
for medical services are still not going down. Therefore it is very necessary for every 
health organizations to analyze the situation. Methods: To study processes for evi-
dences and requirements of quality, information is collected by quantitave method 
and the cross sectional survey form was used. Results: On the service standard 
surveys taken from medical staffs, 56.6% in I level hospitals, 50.0% in II level hos-
pitals and 73.3% in III level hospitals are replied as they follow certain standards 
for their services. But respondents replied as 47.4% of the standards for medical 
services, which is the most percent, are not incompatible for wards. When summa-
rizing the results, we can say it is not clear what service standards the medical staffs 
cared for by the full-time intensivists had a shorter RCC and ventilator days, lower 
expenses and RCC transfer rates (p < 0.001), and higher weaning and complication 
rates (p < 0.05) than those cared for by the part-time and full-time responsible chest 
physicians. Risk factors for mortality variables including APACHE II, transfer to the 
ICU, RCC length of stays, and albumin level. APACHE II, types of physicians staffed, 
transfer to the ICU, RCC length of stays, and Creatinine were the risk factors affecting 
weaning rates in the RCC patients. ConClusions: There were differences in the 
overall use of health care resources and weaning rates among the patients cared 
for by full-time intensivitsts, part-time responsible chest physicians, and full-time 
responsible chest physicians but no difference in adjusting mortality.
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objeCtives: This study focuses on the regulations made by government of India for 
Nutraceuticals labeling requirements and the need of change in the monitoring system in 
the same our objectives for the study were: 1. to understand labeling regulations of 
Nutraceuticals in India. 2. To study labels of selected Nutraceutical products from 
health care market. Methods: For objective first we have studied the regulations 
made by FDA of India regarding Nutraceuticals labeling requirement, for which we 
have used secondary data collection method. For second objective we have collected 
30 samples randomly from Nutraceutical segments from local Pharmacies and stud-
ied the labels carefully. Results: The follow-up by Nutrceuticals manufacturer to 
labeling regulations found very moderate in our study. We found that regulations 
about list of ingredients, nutritional value, declaration regarding veg non-veg, dec-
laration regarding food additives and other crucial parts of label are poorly followed 
by Nutraceutical Manufacturer in India. ConClusions: As we have studied the 
regulations regarding labeling of Nutraceuticals, we found that this regulations are 
sufficient and appropriate. Again through this research work we come to make this 
conclusion that Nutraceutical manufacturer/importer in India are not that much 
serious regarding labeling which is threatening in some aspects so they used to 
make mistakes in labeling knowingly or unknowingly.
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objeCtives: To develop a method of setting a Drug Price Reference Index (DPRI) in 
the Philippines to ensure good value for money in the procurement and reimburse-
ment of essential medicines. Methods: A database of prevailing drug procurement 
prices was created from actual purchase orders submitted in 2012 by government 
procuring entities in the Philippines. The database includes information on the 
unit cost, volumes of procurement, source/supplier/manufacturer, brand, mode of 
procurement and location of the hospital for each formulation and strength of all 
drugs in the National Formulary. Univariate regression analyses were performed 
for commonly sourced essential drugs exploring possible determinants of drug 
costs, which include quantities procured and hospital bed capacity. Further cost-
comparisons were made for other potential determinants such as mode of procure-
ment, supplier/manufacturer and distance of distribution. Results: Price data was 
analyzed for 20 drug products with the highest share of procurement in terms of 
volume and value. Extreme wide variations in unit costs were consistently observed 
for all drugs analyzed. The price differentials, i. e. high/low ratio, was found to be up 
to 60 times when comparing the highest to the lowest priced drugs. The variations 
in prices were not associated by volumes procured, distance of distribution and 
hospital bed capacity. Suppliers were also observed to charge different prices for 
the same brands to different public hospitals, indicating information asymmetry 
on reasonable prices of drugs. ConClusions: Based on the observed wide varia-
tions in drug procurement prices in the Philippines, setting the DPRI at the median 
value for most drugs was found to be an appropriate method to set ceiling prices 
for public sector procurement. For monopolized pharmaceutical products, other 
methods may be more appropriate such as value-based pricing, price negotiations 
and external reference pricing to relevant countries.
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objeCtives: This study aims to review released policies with regards to biosimilar 
products in China, and further understand the external environment that shapes 
the biosimilar market. Methods: A literature review on laws, regulations and 
policies released by key government stakeholders and other additional docu-
ments was performed to fully capture the policy environment for biosimilars in 
China. Results: Multiple policies have been issued at central government level to 
encourage the development of biologics industry in China. Nevertheless, rather than 
in favor of accelerating market access for biologics, those policies are more R&D 
and manufacturing quality control focused. There is no clear regulatory pathway 
for biosimilars in China to date. Due to the lack of clear standard for biosimilars to 
prove their bioequivalence to the originators, biosimilars are treated as new drugs 
at each stage of market access, resulting in a delay of getting approval in China 
market. Currently, local biosimilar developers are actively building their capabilities 
in innovative biologics such as monoclonal antibodies, while MNC players are con-
tinuing to bring in new molecules. As original products’ patent expiry peak period 
is coming, biosimilars, whose prices are relatively affordable, have potential huge 
